Magnus DPHIL - Monte Rosa Senior Development
| GLUE Stock | USD 6.33 0.60 8.66% |
Executive
Magnus DPHIL is Senior Development of Monte Rosa Therapeutics
| Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
| Phone | 617 949 2643 |
| Web | https://www.monterosatx.com |
Monte Rosa Management Efficiency
The company has return on total asset (ROA) of 0.0266 % which means that it generated a profit of $0.0266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0981 %, meaning that it created $0.0981 on every $100 dollars invested by stockholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities. As of September 23, 2025, Return On Tangible Assets is expected to decline to -0.17. In addition to that, Return On Capital Employed is expected to decline to -0.3. The current year's Net Tangible Assets is expected to grow to about 327.7 M, whereas Total Assets are forecasted to decline to about 277.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dawei Xuan | Erasca Inc | N/A | |
| John JD | Edgewise Therapeutics | 61 | |
| MS CPA | Erasca Inc | 58 | |
| John Soglia | Nuvalent | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
| Robert Shoemaker | Erasca Inc | 44 | |
| David MD | Mineralys Therapeutics, Common | 70 | |
| Matthew Metivier | Nuvalent | N/A | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| John Moore | Edgewise Therapeutics | 60 | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Benjamin Lane | Nuvalent | N/A | |
| Jessie Lin | Nuvalent | N/A | |
| Morgan Conn | Century Therapeutics | 56 | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Marc MD | Edgewise Therapeutics | 68 | |
| Leonard MD | C4 Therapeutics | 63 | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Minli Xie | Erasca Inc | N/A | |
Management Performance
| Return On Equity | 0.0981 | ||||
| Return On Asset | 0.0266 |
Monte Rosa Therapeutics Leadership Team
Elected by the shareholders, the Monte Rosa's board of directors comprises two types of representatives: Monte Rosa inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monte. The board's role is to monitor Monte Rosa's management team and ensure that shareholders' interests are well served. Monte Rosa's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monte Rosa's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Filip MD, Chief Officer | ||
| Jennifer Champoux, VP Operations | ||
| Sharon Townson, Chief Officer | ||
| Edmund Dunn, Senior Controller | ||
| Markus MD, CEO President | ||
| John Castle, Chief Scientist | ||
| Magnus DPHIL, Senior Development | ||
| Philip JD, General Counsel | ||
| Andrew Funderburk, Senior Finance | ||
| JD MBA, Chief Officer | ||
| Ajim CFA, Chief Officer | ||
| Owen Wallace, Chief Officer | ||
| Silvia Buonamici, VP Biology | ||
| Phil JD, G Counsel |
Monte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Monte Rosa a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0981 | ||||
| Return On Asset | 0.0266 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | (0.67) % | ||||
| Current Valuation | 140.86 M | ||||
| Shares Outstanding | 61.76 M | ||||
| Shares Owned By Insiders | 0.72 % | ||||
| Shares Owned By Institutions | 99.28 % | ||||
| Number Of Shares Shorted | 8.24 M | ||||
| Price To Earning | 1.91 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.39 | Revenue Per Share | Quarterly Revenue Growth 3.94 | Return On Assets | Return On Equity |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.